Table 2.
Clinical characteristics of TLE patient
| Sex (M/F) | Age (years) | Course (years) | History of AEDs | Source of organization | Pathologic diagnosis |
|---|---|---|---|---|---|
| M | 18 | 3 | VPA/LTG/LEV | LTN | NL, G |
| M | 22 | 10 | CBZ/TPM/PB | LTN | G |
| F | 14 | 4 | LTG/TPM/PB | RTN | NL, G |
| M | 39 | 15 | VPA/TPM/LEV | LTN | NL, G |
| F | 47 | 20 | CBZ/LTG/PHT/PB | LTN | NL, G |
| F | 55 | 5 | PB/OXC/LEV | RTN | G |
| F | 21 | 3 | OXC/LEV/PB | LTN | NL, G |
| M | 17 | 6 | VPA/OXC/LEV | RTN | NL, G |
| F | 9 | 2 | CBZ/PB/LTG | LTN | G |
| M | 33 | 10 | TPM/VPA/LEV/PB | LTN | NL, G |
| M | 28 | 8 | PB/VPA/LEV | RTN | NL, G |
| M | 43 | 20 | CBZ/TPM/LEV/PB | RTN | NL, G |
| F | 36 | 17 | CBZ/LTG/TMP/PB | LTN | NL, G |
| M | 25 | 5 | VPA/LEV/CBZ | LTN | G |
| F | 48 | 23 | CBZ/VPA/LEV | RTN | NL, G |
| M | 33 | 13 | VPA/LEV/PHT | RTN | NL, G |
| M | 27 | 7 | PB/PHT/VPA | LTN | NL, G |
| F | 40 | 20 | CBZ/PB/LTG/LEV | LTN | NL, G |
| M | 38 | 8 | CBZ/VPA/LEV/PB | RTN | NL, G |
| M | 67 | 33 | PHT/TPM/PB | LTN | G |
E epilepsy, M male, F female, AEDs antiepileptic drugs, VPA valproic acid, LTG lamotrigine, LEV levetiracetam, CBZ carbamazepine, TPM topiramate, PB phenobarbital, PHT phenytoin, OXC oxcarbazepine, LTN left temporal neocortex, RTN right temporal neocortex, NL neuronal necrosis, G glios